The 31st Huading Awards “Global Film Satisfaction Survey” Release the Winners in Los Angeles
Group of Ex-Goldman Sachs, Morgan Stanley Execs Join Crypto Unicorn Amber Group
LEAD Horizon: How travelers in Austria gargle against the corona virus
Transcenta Received IND Clearance from NMPA of its Anti-sclerostin Monoclonal Antibody TST002
Accommodating Over 1 Million Servers, World's Largest HUAWEI CLOUD Data Center Comes into Service in Gui'an
Innovent and AnHeart Announce Interim Data from Phase 2 Trial of Taletrectinib in ROS1-Positive NSCLC at the CSCO 2021 Annual Meeting
Château Quintus Grows with the Acquisition of Château Grand-Pontet
TransPerfect Wins Contempt Motion Victory Against Custodian-Hired Law Firm
New Study Evaluates the Feasibility of Using Masimo EMMA® Capnography on Mechanically Ventilated Neonates
Genesis Executes the First OTC Trade of an Innovative New Bitcoin Futures Product with Akuna Capital
-
Nebula Brands - China’s “Thrasio” - Starts to Acquire Amazon Brands
HONG KONG--(BUSINESS WIRE)--Thrasio, the American Amazon aggregator, has recently announced an additional $650 million in commitments to its senior credit facility, bringing the total amount of capital raised to more than $2 billion within less than two years and it has acquired more than 150 potential brands on Amazon and other e-commerce platforms. The key feature of the Thrasio-style investment model is that the company can buy good brands at lower prices and then run these existing brands through large-scale, data-driven operations, hoping to build an online version of P&G with multiple brands and marketplaces. Nebula Brands, China’s Thrasio, also raised a large amount of money from well-known international and domestic fund companies after joining the game early this year. “Over 40% of third-party sellers and 70% goods on Amazon are from China and many brands are taking the lead in their categories relying on their advantages of manufacturing. As for Nebula Brands, a variety of acquirable brands, a supply chain covering the whole industries and talents with engineering background are essential to participate in the global competition,” said William Wang, co-founder of Nebula Brands. A few days ago, Nebula Brands announced that it has completed its first several acquisitions. The one already revealed is a yoga headstand bench brand, which is one of the top brands in its category on Amazon. The company has built professional teams of brand marketing, production R&D, supply chain management and other modules in Beijing, Shenzhen and New York. After the acquisition, optimization tactics regarding package, ads and production lines in various dimensions have also been applied in order to improve the quality of products and competitiveness of brands, resulting in an over 50% year-over-year increase in sales on Amazon. As the company acquires more brands, the brand effect will increase in scale. That’s why Nebula Brands is intensifying its input in technology to improve its capability of multi-brand, multi-channel and multi-module management. Currently, the model has already attracted nearly $10 billion worldwide to date, with more and more funds flowing to leading aggregators. Nebula Brands said that it will continue its acquisitions in sports, maternal and child supplies, health, home furnishings and other areas with its equity funds and debt funds raised from the United States, Europe and Hong Kong, hoping to increase its competitive edge following Thrasio model. Contacts William Wang 18669338926 william.w@nebula.site
-
College of American Pathologists Honors 31 Members/Residents at CAP21 Annual Meeting
W. Stephen Black-Schaffer, MD, FCAP Named Pathologist of the Year CHICAGO--(BUSINESS WIRE)--#AnnualMeeting--The College of American Pathologists (CAP), the world’s largest organization for the medical doctors who diagnose and study disease, recognized several of its members for their contributions to pathology and laboratory medicine during CAP21 “Advancing Medicine Today & Tomorrow.” Meeting participants had the option to attend virtually or in-person at the Hyatt Regency in Chicago, Illinois, September 25-28, 2021. In recognition of his long and distinguished career in pathology, the CAP named W. Stephen Black-Schaffer, MD, FCAP, with the Pathologist of the Year Award. Dr. Black-Schaffer has served on many committees, councils, and task forces during his 30 years as a CAP member. He currently chairs the Policy Round Table Workforce and Graduate Medical Education Workgroup and the Economic Affairs Committee (EAC). “There is no lack of pathologists whose accomplishments stand out in fields from basic science to public health,” states Dr. Black-Schaffer. “I am grateful to be honored, and I would like to say thank you, not just for the award, but much more for enabling me to find friends among colleagues from across the nation, and to effect changes in public policy and practice, none of which would have been possible without the College to bring its members together, and the College staff to educate and empower us.” Throughout his career, he has assumed local and national leadership roles while actively engaging in education and advocacy, both vital to pathology. He served as a member of the initial Accreditation Council for Graduate Medical Education (ACGME) pathology milestone project teams, providing a critical roadmap for pathology training. He chaired the American Society of Cytopathology Taskforce on Cytopathology Qualifications for Pathology Residency Programs. As a leader in advocacy, he has been the Massachusetts representative to his regional Medicare Contractor Advisory Committee since 1992. As EAC chair, he has effectively explained the importance of fair pathology reimbursement to federal regulatory authorities, congressional staff, and private payer medical directors. Dr. Black-Schaffer is currently an associate professor of pathology at Harvard Medical School, and associate chief of pathology and Pathology Residency Training Program director at Massachusetts General Hospital. In addition to the Pathologist of the Year award, the CAP recognized 30 other members/residents for their contributions, achievements, and service in a multitude of areas, including but not limited to advocacy, patient care, education, quality improvement programs, and communications. The CAP annually honors members for their commitment to the specialty and quality patient care. This year’s honorees are: CAP Advocate of the Year Award David L. Gang, MD, FCAP CAP Distinguished Patient Care Award Mary E. Fowkes, MD, PhD, FCAP CAP Distinguished Service Award Rajesh C. Dash, MD, FCAP Eva M. Wojcik, MD, FCAP CAP Laboratory Accreditation Program Service Award Gregory A. Gagnon, MD, FCAP CAP Laboratory Improvement Programs Service Award Christina M. Wojewoda, MD, FCAP Daniel D. Rhoads, MD, FCAP CAP Lifetime Achievement Award David N. Alter, MD, DABCC, FCAP Christine N. Booth, MD, FCAP Andrew J. Evans, MD, PhD, FRCPC, FCAP David A. Novis, MD, FCAP John D. Olson, MD, PhD, FCAP R. Ross Reichard, MD, FCAP CAP Outstanding Communicator Award Valerie A. Fitzhugh, MD, FCAP CAP Outstanding Educator Award Robert D. Hoffman, MD, PhD, FCAP CAP Outstanding Service Award Paul Bachner, MD, FCAP CAP Pathology Advancement Award David F. Keren, MD, FCAP Mark S. Synovec, MD, FCAP Kamran M. Mirza, MD, PhD, FCAP Cullen M. Lilley, MS Christina A. Arnold, MD, FCAP Michael A. Arnold, MD, PhD, FCAP Adam L. Booth, MD Jerad M. Gardner, MD, FCAP Xiaoyin "Sara" Jiang, MD, FCAP Sanam Loghavi, MD, FCAP CAP Public Service Award Sarah M. Eakin, MD, FCAP CAP Resident Advocate Award Nicole D. Riddle, MD, FCAP CAP Resident of the Year Award Mariam Anwar Molani, DO, MBA CAP Staff Outstanding Achievement Award Mary F. Kennedy, MPH, CT(ASCP) About the College of American Pathologists As the world's largest organization of board-certified pathologists and leading provider of laboratory accreditation and proficiency testing programs, the College of American Pathologists (CAP) serves patients, pathologists, and the public by fostering and advocating excellence in the practice of pathology and laboratory medicine worldwide. For more information, read the CAP Annual Report. Contacts Catherine Dolf, Sr. Manager, Media Relations CAP, 847-832-7472, cdolf@cap.orgAbby Watson, Manager, Communications CAP, 847-832-7513, awatson@cap.org
-
Kintor Pharma Announces Brazil's ANVISA Approves Phase III Clinical Trial of Proxalutamide for the Treatment of Hospitalized COVID-19 Patients
SUZHOU, China, Sept. 26, 2021 /PRNewswire/ -- Kintor Pharmaceutical Limited ("Kintor Pharma", HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecule and biological therapeutics, today announced that on September 22 the Brazilian Health Regulatory Agency (ANVISA) granted an approval for the phase III clinical trial of proxalutamide to treat hospitalized COVID-19 patients. This is the third ANVISA-approved pivotal study sponsored by Kintor Pharma for the treatment of COVID-19 patients with proxalutamide. The phase III trial (NCT05009732) is a randomized, double-blind, placebo-controlled, multi-regional clinical study, which is expected to enroll 1,030 patients, designed to evaluate the efficacy and safety of proxalutamide in hospitalized COVID-19 patients. The primary endpoint of the trial is the time to sustained recovery evaluated by day 30. The secondary endpoint of the trial is 30-day mortality. Dr. Youzhi Tong, founder, Chairman, and CEO of Kintor Pharma, commented, "The approval of this study represents another milestone for Kintor Pharma. We have been planning to conduct the pivotal multi-regional clinical trial of proxalutamide for the treatment of hospitalized COVID-19 patients in more than ten countries. With this third approval by ANVISA, Brazil becomes the fourth country to approve the proxalutamide clinical trial after the United States, China and Philippines. We are hopeful this approval will pave the way for Kintor Pharma to apply for an emergency use authorization (EUA) and the eventual commercialization of proxalutamide for the treatment of COVID-19 in Brazil." About Proxalutamide (GT0918)Proxalutamide is a nonsteroidal antiandrogen — specifically, a selective high-affinity silent antagonist of the androgen receptor — that is under development for the potential treatment of COVID-19, prostate cancer, and breast cancer. Targeting AR-ACE2/TMPRSS2 signal axis by proxalutamide could significantly inhibit the entry of the virus into host cells by transcriptionally down-regulating the expression of TMRPSS2 and ACE2. Meanwhile, proxalutamide promotes the clearance of pathogens and decreases inflammation by activating the Nrf2 pathway, which activates several antioxidative genes and proteins, and reduces the intensity of the cytokine response, which may be of clinical benefit to patients with COVID-19 infection. Kintor Pharma is now conducting two registered phase III multi-regional clinical trials (MRCT) of proxalutamide for the treatment of COVID-19 outpatients, and one phase III MRCT for COVID-19 inpatients in countries and regions that include the United States, South America (including Brazil), the European Union, and Asia. Kintor Pharma was granted an emergency use authorization (EUA) for proxalutamide for the treatment of COVID-19 infection in hospitalized patients in Paraguay. About Kintor Pharmaceutical LimitedKintor Pharmaceutical Limited is developing and commercializing a robust pipeline of innovative small molecule and biological therapeutics for androgen-receptor-related disease areas with unmet medical needs, including COVID-19, prostate, breast and liver cancer, alopecia and acne. For more information, visit www.kintor.com.cn. Contact InformationIR Team:Kintor PharmaIR@kintor.com.cn Solebury TroutBob Aibai@soleburytrout.com PR Team:Kintor PharmaPR@kintor.com.cn MessagingLABKarl SchmiederKarl@messaginglab.com Related Links :http://www.kintor.com.cn
-
GenScript ProBio and AskGene Enter into a Non-exclusive License of A sdAb Targeting Immune Checkpoint Target
NANJING, China, Sept. 26, 2021 /PRNewswire/ -- On September 26, 2021, GenScript ProBio and AskGene signed a license agreement for GenScript ProBio's single-domain antibody (sdAb) targeting an immune checkpoint target. GenScript ProBio grants a non-exclusive global license to AskGene to use GenScript ProBio's sdAb targeting immune checkpoint target for discovery, development and commercialization of its antibody and derivative products. In the future, GenScript ProBio will be the preferred partner for CMC development, clinical and commercial manufacturing of this product. AskGene, founded in 2012 in Los Angeles, California, is aspired to become the leader in the cytokine prodrug field. The sdAb involved in this license agreement will be paired with AskGene's proprietary next-generation cytokine therapeutics for cancer immunotherapy and other applications. Compared with traditional antibodies, single-domain antibodies feature lower molecular weight, higher stability, and easier recombinant expression. Since the establishment of its sdAb discovery platform in 2010, GenScript has accumulated over 11 years of sdAb research and development experience. At present, GenScript ProBio has built up integrated sdAb immune library, sdAb naïve library, sdAb humanization, antibody screening and functional validation platforms. GenScript ProBio has so far reached 6 licensing deals on sdAb products with global biotech and pharma. "We are very glad to cooperate with AskGene, a team of experienced scientists, and we feel so honored to provide support for the promising next-generation cytokine therapeutic projects," Dr. Brian Min, CEO of GenScript ProBio said. "I believe the cooperation will further show the technology and platform advantages of both parties. We will keep an eye on the progress of this project and look forward to using GenScript ProBio's solid CMC development experience to accelerate the project to clinic application and benefit patients." AskGene's Jeff Lu, Ph.D., CEO, said, "GenScript ProBio has profound accumulation and core competitiveness in single domain antibody discovery. We are very pleased to cooperate with this highly professional CDMO company to support us in developing the promising next-generation cytokine therapeutics to benefit patients. We look forward to cooperating with GenScript ProBio to jointly accelerate the transformation of medicine and create a better future." About AskGene Pharma Inc AskGene (California, USA), founded in 2012 in Los Angeles, California, is pioneering the development of next generation cytokine therapeutics. It is led by an experienced team with proven track records of developing novel biologics. AskGene has established the cutting edge SmartKine® cytokine prodrug platform. The SmartKine® platform significantly improves the developability of cytokines for oncology and inflammation indications. AskGene is actively moving multiple projects into clinical and preclinical developments. About GenScript ProBio GenScript ProBio is the biologics CDMO segment of GenScript, proactively providing end-to-end service from drug discovery to commercialization with proactive strategies, professional solutions and efficient processes in antibody drug and gene and cell therapy to accelerate drug development for customers. GenScript ProBio's innovative solutions for antibody drug development include antibody drug discovery, antibody engineering and antibody characterization. In terms of biologics development service, GenScript ProBio has built a regulatory-compliant platform, from stable cell line development, host cell license, process development, analytical development to clinical manufacturing services, providing fed-batch and perfusion process to accelerate IND process and high quality material for clinical trials. GenScript ProBio has successfully delivered multiple CMC and GMP manufacturing projects. GenScript ProBio's total gene and cell therapy solution covers CMC of plasmid and virus for IND filing as well as clinical manufacturing and commercial manufacturing. Our quality management systems ensure phase appropriate compliance, data integrity and traceability. https://www.genscriptprobio.com
-
Spirit of Wipro Run Brings Together Participants From Over 35 Countries
NEW YORK & PARIS & BANGALORE, India--(BUSINESS WIRE)--#BusinessProcessServices--Wipro Limited (NYSE: WIT, BSE: 507685, NSE: WIPRO), a leading global information technology, consulting and business process services company, today organized the 16th annual ‘Spirit of Wipro’ (SOW) Run, drawing thousands of participants from over 35 countries to run together in spirit. For the past sixteen years, Wiproites around the world have come together to celebrate Wipro’s core values. The annual SOW run aims to inspire employees to be responsible citizens of the world. This year’s theme was “Together. To greatness,” inspired by the resilience demonstrated by Wiproites in a year of unprecedented disruption. Along with outperforming across all business parameters, Wipro teams have remained committed to supporting their colleagues and creating a lasting social impact across communities. Like last year, this year’s race was also virtual, and runners strictly adhered to the local COVID-19 guidelines and safety protocols while participating in the event. Even under these conditions, enthusiasm was high. Participants used the freely available Strava app to track their progress and keep connected with fellow runners around the world. Wipro also encouraged employees to share selfies and videos leading up to and throughout the day of the race, which the company curated and shared on internal channels and on social media. Every year, all proceeds from the Spirit of Wipro Run are matched 100% by Wipro and is utilized by Wipro Cares, the community initiatives arm of Wipro Limited. In the past, these donations went primarily to support the education of disadvantaged children. In 2020, most of the proceeds were directed towards the pandemic relief efforts and will continue for this year as well. Through these contributions and the company’s larger community impact, Wipro continues to work towards its vision of creating a more equitable and sustainable society for all. After participating in the event, Thierry Delaporte, Chief Executive Officer and Managing Director, Wipro Limited said, “Wipro’s commitment to progress goes beyond digital innovation and business transformation. The Spirit of Wipro Run is a testament to that. We are a global family driven by a shared commitment — that of supporting one another, of pursuing healthier futures, and giving back to our communities.” Saurabh Govil, President and Chief Human Resources Officer, Wipro Limited said, “After such a humbling year, it is moving to see Wiproites across the world coming together, albeit virtually. The Spirit of Wipro Run embodies the values and culture that make us a resilient, purpose-driven organization. We believe the contributions from the event will help create a positive impact on local communities across the countries where we operate.” About Wipro Limited Wipro Limited (NYSE: WIT, BSE: 507685, NSE: WIPRO) is a leading global information technology, consulting and business process services company. We harness the power of cognitive computing, hyper-automation, robotics, cloud, analytics and emerging technologies to help our clients adapt to the digital world and make them successful. A company recognized globally for its comprehensive portfolio of services, strong commitment to sustainability and good corporate citizenship, we have over 200,000 dedicated employees serving clients across six continents. Together, we discover ideas and connect the dots to build a better and a bold new future. Forward-Looking Statements The forward-looking statements contained herein represent Wipro’s beliefs regarding future events, many of which are by their nature, inherently uncertain and outside Wipro’s control. Such statements include, but are not limited to, statements regarding Wipro’s growth prospects, its future financial operating results, and its plans, expectations and intentions. Wipro cautions readers that the forward-looking statements contained herein are subject to risks and uncertainties that could cause actual results to differ materially from the results anticipated by such statements. Such risks and uncertainties include, but are not limited to, risks and uncertainties regarding fluctuations in our earnings, revenue and profits, our ability to generate and manage growth, complete proposed corporate actions, intense competition in IT services, our ability to maintain our cost advantage, wage increases in India, our ability to attract and retain highly skilled professionals, time and cost overruns on fixed-price, fixed-time frame contracts, client concentration, restrictions on immigration, our ability to manage our international operations, reduced demand for technology in our key focus areas, disruptions in telecommunication networks, our ability to successfully complete and integrate potential acquisitions, liability for damages on our service contracts, the success of the companies in which we make strategic investments, withdrawal of fiscal governmental incentives, political instability, war, legal restrictions on raising capital or acquiring companies outside India, unauthorized use of our intellectual property and general economic conditions affecting our business and industry. The conditions caused by the COVID-19 pandemic could decrease technology spending, adversely affect demand for our products, affect the rate of customer spending and could adversely affect our customers’ ability or willingness to purchase our offerings, delay prospective customers’ purchasing decisions, adversely impact our ability to provide on-site consulting services and our inability to deliver our customers or delay the provisioning of our offerings, all of which could adversely affect our future sales, operating results and overall financial performance. Our operations may also be negatively affected by a range of external factors related to the COVID-19 pandemic that are not within our control. Additional risks that could affect our future operating results are more fully described in our filings with the United States Securities and Exchange Commission, including, but not limited to, Annual Reports on Form 20-F. These filings are available at www.sec.gov. We may, from time to time, make additional written and oral forward-looking statements, including statements contained in the company’s filings with the Securities and Exchange Commission and our reports to shareholders. We do not undertake to update any forward-looking statement that may be made from time to time by us or on our behalf. Contacts Nisha Chandrasekaran Wipro Limited nisha.chandrasekaran@wipro.com
-
JW Therapeutics Announces Updated 1-year Follow-up Result of Relmacabtagene Autoleucel Injection At the 24th Annual Meeting of the Chinese Society of
SHANGHAI, Sept. 26, 2021 /PRNewswire/ -- JW Therapeutics (HKEx: 2126), an innovative biotechnology company focused on developing, manufacturing and commercializing cell immunotherapy products, today announced updated 1-year follow-up result of relmacabtagene autoleucel injection (relma-cel) for the treatment of relapsed or refractory large B-cell lymphoma (r/r LBCL) at the 24th Annual Meeting of the Chinese Society of Clinical Oncology (CSCO). RELIANCE Study was a phase II, open-label, single-arm, multi-center clinical study in China, which included 59 adult patients with r/r LBCL who had failed at least 2 lines of previous treatment. As of the December 31st, 2020 data cut-off, in 58 evaluable patients, results include: Relma-cel showed durable responses and long-term survival benefit; the Best Overall Response Rate was 77.6%, the Best Complete Response Rate was 51.7% and 1-year Overall Survival (OS) was 76.8% with a median follow-up of 17.9 months; Relma-cel was generally well-tolerated with a safety profile including a low severe Cytokine Release Syndrome (≥grade 3) of 5.1% and a low severe neurotoxicity rate (≥grade 3) of 3.4%, and no new safety signals with a median of 17.9 months of follow up; Long-term follow-up of the RELIANCE study have confirmed the durability of response and long-term OS with relma-cel treatment, which also was associated with low rates of CAR-T-associated toxicities. "Large B-cell lymphoma (LBCL) is the most common and aggressive type of non-Hodgkin lymphoma and most patients relapse after initial therapies with limited treatment options with standard therapies and a median survival of approximately 6 months," said Mark J. Gilbert, Chief Medical Officer of JW Therapeutics, "These long-term follow-up data reported from the RELIANCE study have confirmed the durability of responses after relma-cel treatment, representing a potentially important treatment option for these patients that appears to offer clear hope of longer survival in these patients." Reference: Crump M, Neelapu SS, Farooq U, Van Den Neste E, Kuruvilla J, Westin J, Link BK, Hay A, Cerhan JR, Zhu L, Boussetta S, Feng L, Maurer MJ, Navale L, Wiezorek J, Go WY, Gisselbrecht C. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood. 2017 Oct 19;130(16):1800-1808. doi: 10.1182/blood-2017-03-769620. Epub 2017 Aug 3. Erratum in: Blood. 2018 Feb 1;131(5):587-588. PMID: 28774879; PMCID: PMC5649550. About Relmacabtagene Autoleucel Injection (trade name: Carteyva®) Relmacabtagene autoleucel injection (trade name: Carteyva®) is an autologous anti-CD19 CAR-T cell immunotherapy products that was independently developed by JW Therapeutics based on a CAR T cell process platform of Juno Therapeutics (a Bristol Myers Squibb company). The first product of JW Therapeutics, relma-cel was approved by the China National Medical Products Administration (NMPA) in September 2021 for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, making it the first CAR-T product approved as a Category 1 biologics product in China. Currently, it is the only CAR-T product in China that has been simultaneously included in the National Significant New Drug Development Program, granted priority review and breakthrough therapy designations. About RELIANCE Study (NCT04089215) RELIANCE study was a single-arm, multi-center, pivotal study to evaluate the efficacy and safety of relmacabtagene autoleucel injection (relma-cel) in patients with relapsed or refractory large B-cell lymphoma (r/r LBCL) in China. At the time it was conducted, this study was the largest clinical study of CAR-T cell therapy in China under the Investigational New Drug (IND) pathway. RELIANCE study enrolled 59 patients with r/r LBCL who had failed at least two lines of therapy, including a CD20 agent and anthracycline, and patients continue to be monitored for up to 2 years and beyond for long term outcomes. As of the December 31st, 2020 data cut-off, the Best Overall Response Rate was 77.6% with a Best Complete Response Rate of 51.7%, and 12-month Overall Survival (OS) was 76.8% in 58 evaluable patients; With a median follow-up of 17.9 months, of 59 treated patients, 5.1% and 3.4% of the patients experienced Cytokine Release Syndrome (CRS) and Neurotoxicity (NT) of Grade 3 or above, respectively. Rates for any severity grade CRS and NT were 47.5% and 20.3%, respectively. Long term follow up of the RELIANCE study have confirmed the durability of response and long-term OS with relma-cel treatment, which also was associated with low rates of CAR-T-associated toxicities. About JW Therapeutics JW Therapeutics (HKEx: 2126) is an innovative biotechnology company focusing on developing, manufacturing and commercializing cell immunotherapy products. Co-founded by Juno Therapeutics (a Bristol Myers Squibb company) and WuXi AppTec in 2016, JW Therapeutics is committed to becoming an innovation leader in cell immunotherapy. The company has built a top world-class platform for technology and product development in cell immunotherapy, as well as a promising product pipeline covering both hematologic malignancies and solid tumors, to bring the hope of a cure for Chinese and global patients, and to lead the healthy and standardized development of China's cell immunotherapy industry. For more information, please visit www.jwtherapeutics.com. Forward-Looking Statements The forward-looking statements are based on the management's expectations and beliefs and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described. Significant risks and uncertainties, include those discussed below and more fully described in Hong Kong Exchanges and Clearing Limited (HKEx) reports filed by the Company. Unless otherwise noted, the Company is providing this information as of the date it publicized, and expressly disclaims any duty to update information contained in the issues and relevant information, or provide any explanation. For detailed information, please visit the company website: www.jwtherapeutics.com/en/forward-looking-statements/.Related Links :http://www.jwtherapeutics.com
-
The 2nd APEC Cross-Border E-Commerce Training Workshop Concluded Successfully
DHgate Conveys China’s Experience BEIJING--(BUSINESS WIRE)--#commerce--The 2nd APEC Cross-Border E-Commerce Training Workshop (APEC CBET II), hosted by Ministry of Commerce, People's Republic of China, supported by DHgate, Hong Kong, China, Indonesia, Peru, and Russia co-sponsoring, was successfully concluded in Beijing. Celebrity guest speakers, including famous scholars and experts, senior executives from trade associations and private sectors, shared unparalleled insights and experience in developing the digital economy. Government officials from more than 10 APEC economies, including Canada, Japan, Singapore, Thailand, and others, as well as multiple ministries and departments of PRC and other representatives, a total of more than 150 people, participated in the workshop. The APEC CBET II covers a broad spectrum of topics, including challenges and opportunities of global trade, the APEC digital economy integration, trends of cross-border e-commerce, trade policies of improving the efficiency and management of supply chain, and reopening borders initiatives. Meanwhile, it also focuses on execution, from public policymaking, standard operation, innovative technology adoption, cross-border payments, financial loans, logistics construction, a new style of e-commerce, to the latest marketing trends. Mr. Song Yang, Director of Department of International Trade and Economic Affairs, Ministry of Commerce, said in his closing remarks, "This workshop identified precious takeaways of policy recommendations for boosting e-commerce and digital trade for the region in the context of the pandemic, which will profoundly benefit and shape APEC's future discussions in this regard." According to a World Economic Forum report, the total global trade shrank by 8.9% in 2020, marking the worst recession since the 2008 financial crisis. However, innovative technologies represented by artificial intelligence (AI), digitalization, and the Internet are becoming critical driving forces for the development of APEC and even the global economy, and further bolster the paradigm upgrade of global economic growth, which will reshape organization methods, economic processes, and economic profit. The changes also happen in the area of cross-border e-commerce. In August 2020, based on its strong technical capabilities and rich experience in the cross-border B2B practice, DHgate launched MyyShop, a decentralized cloud-based e-commerce SaaS solution that aims to help MSMEs, especially entry-level people and start-up micro merchants, and monetize their social networks. MyyShop provides intelligent selection and distribution services, enabling dropshippers to establish and scale their business environment quickly. It is committed to serving as a one-stop platform providing services ranging from interactive site building, source selection from reliable areas, selection of quality product to drop shipping, the best-in-class distribution system, and customer-friendly after-sales services. It also supports synchronization with users' other social media channels and e-commerce platform accounts to quickly monetize private domain traffic. Mr. Billy Deng, Vice President of DHgate, said at the APEC CBET II, "The pandemic-driven e-commerce boom has accelerated the growth of social e-commerce. MyyShop is an innovative supply chain solution in line with this global trend. We have helped more than 30,000 African MSMEs in 3 months to start up cross-border e-commerce businesses with a light budget. By 2025, MyyShop is expected to help 1.05 million MSMEs and individuals in Africa with this business model, which has strong innovation vitality and can be widely promoted to APEC economies as well." To address the challenge that MSMEs always lack sufficient funds and credit for developing businesses, Ms. Zoe Zuo, Operation Director of Tuotuo Digital, shared the best practice of the e-commerce loan jointly launched with China Construction Bank. Leveraging the neural network-based big data model, Random Forest algorithm, and GBDT model, Tuotuo Digital has been able to use millisecond-level operation and massive data from various scenarios to establish an efficient risk control model. With an AI-assisted decision-making system, it can complete the integration of Loan/Repayment business between MSMEs and the bank within one second. While greatly simplifying and facilitating loans for MSMEs, it also soundly manages risks. Impacted by COVID-19, the shortage of cross-border logistics capacity and surging prices have drawn much attention. In particular, the five-fold increase in shipping prices between China and the United States has become a hot topic. Mr. Oliver Wan, Head of DHLink of DHgate, called for regular meetings among governments of APEC economies to align policies and supervision of the logistics industry, give the international logistics industry more flexibility and development space in the region and make prices more affordable. The expenses must return to normal as soon as possible, which can help MSMEs and individual practitioners reduce operating costs. About the Cross-Border-E-Commerce Training (CBET) The project was launched by Ms. Diane Wang who is the Founder, Chairperson and CEO of DHgate at the APEC ministerial meeting in Bali. The CBET's main goal is to introduce the booming cross-border e-commerce to MSMEs around the world through training, enabling them to integrate into the global industrial chain, lift out of poverty, start up and upgrade via cross-border e-commerce. At present, the project is quite far-reaching, which has trained more than 10,000 entrepreneurs, business association representatives and policymakers from more than 20 economies. Contacts Georgina Lv Tel: (86) 10 - 8202 8870 ext.8908 lvchenxing@dhgate.com
-
All-China Environment Federation Making Efforts to Mainstream Biodiversity at CBD COP15
KUNMING, China, Sept. 26, 2021 /PRNewswire/ -- According to China Environment News: The 15th Conference of the Parties to the Convention on Biological Diversity (CBD COP15) will be held in October, 2021, at which representatives from governments, enterprises, NGOs, media and other organizations around the world will gather in Kunming to discuss around the theme of "Ecological Civilization: Building a Shared Future for All Life on Earth" and release the "Kunming Declaration". As one of the eight parallel forums of CBD COP15, the NGO Parallel Forum will be held in Kunming from 27 to 28 September 2021. During the forum, All-China Environment Federation (ACEF) will host the theme forum "Environmental NGOs' Role in Biodiversity Mainstreaming" in joint with International Union for Conservation of Nature(IUCN). This forum will invite NGOs from different countries in fields of ecological protection, climate change, sustainable consumption, and pollution prevention and control etc. to exchange and form concerted efforts on biodiversity conservation mainstreaming. Practical experiences and outstanding cases will be shared and the "Environmental NGOs' Joint Statement on Biodiversity Conservation Mainstreaming" will also be released by the end of the forum. Relevant institutions such as the government, private sectors, think tanks, and media will also be invited from the perspective of multi-stakeholders. Through incorporating the UN SDGs, all the attendees are expected to discuss and figure out both the opportunities and the challenges for future cooperation on mainstreaming biodiversity conservation as well as building a dialogue and collaboration platform for NGOs and multi-stakeholders. 1. Time September 27, 2021 14:00-16:00 (Beijing Time) 2. Live Streaming Chinese:https://weibo.com/l/wblive/p/show/1022:2321324685441587609873 English:https://www.youtube.com/playlist?list=PLjpSs1uejVAkz6Zw5YRp-FPVhJCScVX1V 3. Support Biodiversity Mainstreaming Please Contact acefgjb@sina.com for details 4. Forum Agenda 14:00-14:05 Opening Video Living in Harmony with Nature 14:05-14:25 Keynote Speech Moderator: XIE Yuhong, Vice Chairperson and Secretary General, All-China Environment Federation (ACEF) 1. Mainstreaming: The Main Tool for Achieving the Post-2020 Global Biodiversity Framework Oliver HILLEL, Programme Officer for Mainstreaming, Secretariat of the Convention on Biological Diversity 2. China's Main Policies and Measures of Accelerating Biodiversity Mainstreaming LIU Ning, Deputy Executive Director of Executive Committee of the Office of the Executive Committee for COP15, Ministry of Ecology and Environment (MEE) and Chief Negotiator of the Chinese delegation 3. From Marseille to Kunming – Biodiversity Mainstreaming and the Role of NGOs ZHANG Yan, China Country Coordinator, International Union for Conservation of Nature (IUCN) 14:25-15:15 Topic Sharing: Practical Experience Sharing in Promoting Biodiversity Conservation Mainstreaming Moderator: NI Yao, Deputy Director, Department of International Cooperation, ACEF 1.From the perspective of Ecological Protection LIAO Haohong, Yunnan Program Senior Manager, the Nature Conservancy SHAN Shuo, Deputy Director, Professional Committee on Sustainable Use of Plants of China Wild Plant Conservation Association 2.From the perspective of Sustainable Energy CHENG Zhiqiang, Deputy Secretary General, Global Energy Interconnection Development and Cooperation Organization LIU Zuming, Coucil Member, China Renewable Energy Society 3.From the perspective of Pollution Control XIE Xi, Project Lead, Friends of Ocean Action, World Economic Forum LIU Sheng, Secretary General of Warder of Rivers 4.From the perspective of Cross-cutting Issue Jocely BLÉRIOT, Executive Lead - Institutions, Governments and Cities at Ellen MacArthur Foundation WANG Wenhua, Deputy Secretary General of China Chain-Store & Franchise Association 15:15-15:55 Roundtable: Opportunities and Challenges for Multi-stakeholder Collaboration in Biodiversity Mainstreaming Moderator: WANG Xiangyi, Vice Chairperson and Executive Director, China Association for NGO Cooperation (CANGO) -Goverment Representative: Christoffer Gronstad, Environmental Counselor of the Norwegian Embassy in China -Think Tank Representative: XU Qinhua, head of National Academy of Belt and Road Green Development (NABRGD), CICEC -Enterprise Representative: WANG Hanyun, Assistant General Manager of Huzhou Grid Corporation -Financial Institution Representative: WANG Ying, Head of Corporate Sustainability, HSBC Media Representative: LIU Jia, Audience Development Executive of PR Newswire -KOL Representative: YANG Xiaoyang (Fruit Hunter), BiliBili creator 15:55-16:00 Releasing Environmental NGOs' Joint Statement on Biodiversity Mainstreaming XIE Yuhong, Vice Chairperson and Secretary General, ACEF
-
CBD COP15 NGO Parallel Forum to be held soon
Multi-stakeholder Perspectives Contributing to the Kunming Declaration on Biodiversity ConservationKUNMING, China, Sept. 26, 2021 /PRNewswire/ -- According to The China Environment News: As one of the eight parallel forums of the The Fifteenth Meeting of the Conference of the Parties (CBD COP 15) to the Convention on Biological Diversity, the NGO Forum will be held in Kunming from 27 to 28 September 2021. More than 400 representatives of government, enterprise, NGO, Youth group, Women group, local community and indigenous peoples from more than 30 countries on five continents participate in the forum online and offline, sharing their cutting-edge views, actions and cases around the negotiation of Post-2020 Global Biodiversity Framework, biodiversity mainstreaming, and voluntary commitments from non-state actors, etc. NGO forum will bring together stakeholders from all walks of life to contribute to the official CBD COP15 meeting on October 11 and the Kunming Declaration to be released at that time. 1. Live Streaming Chinese:https://weibo.com/l/wblive/p/show/1022:2321324685441587609873 English:https://www.youtube.com/playlist?list=PLjpSs1uejVAkz6Zw5YRp-FPVhJCScVX1V 2. Forum Overview 2.1 Organizers Organized by: Secretariat of the Convention on Biological Diversity, the Ministry of Ecology and Environment, the China NGO Network for International Exchanges Supported By: China Environmental Protection Foundation (CEPF), Civil Society Alliance for Biodiversity Conservation (PFI, SEE, GEI, and ShanShui), All-China Environment Federation(ACEF), Client Earth, CI, China Eco-Civilization Research and Promotion Association (CECRPA) 2.2 Brief Agenda September 27 9:00-10:30 Opening Ceremony and Roundtable 10:30-12:00 Forum-1: Nature-based Solutions to Climate Change—ASEAN-China Mangroves Ecological Corridor 14:00-16:00 Forum-2: Environmental NGO's Role in Biodiversity Conservation Mainstreaming 16:30-18:30 Forum-3: Release of the "Global Biodiversity Conservation Best Practices 100+ " and Discussion 19:30-21:30 Biodiversity Carnival Night September 28 9:00-11:30 Forum-4: Independent Contributions from Non-state Actors and the Post-2020 Goal for Biodiversity Conservation 13:00-16:00 Forum-5: Foundations Contributing to Biodiversity Conservation 16:30-17:30 Closing Ceremony: Signing of the Independent Contribution Initiative by Non-State Actors
-
Lorem Ipsum Dolor Sit Amet, Consectetur Adipiscing Elit
Aenean tincidunt luctus sem, et euismod ante auctor a SAN FRANCISCO--(BUSINESS WIRE)--Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aenean tincidunt luctus sem, et euismod ante auctor a. Quisque turpis magna, ultricies et facilisis vitae, interdum vitae turpis. Sed interdum sagittis lectus, at pretium velit. “In eleifend a nulla et fringilla.” Etiam imperdiet purus enim, non interdum mi porttitor vel. Morbi nunc massa, sodales a nunc eu, laoreet ultricies quam. Aliquam sodales arcu vel felis venenatis faucibus. Vestibulum nunc odio, porta et tincidunt at, pellentesque at est. Nullam sagittis libero faucibus ornare cursus. Donec feugiat metus in nisl posuere tempus. Donec congue augue nibh, a tincidunt purus lacinia id. Vestibulum ante ipsum primis in faucibus orci luctus et ultrices posuere cubilia Curae; “Nam eget ipsum ac libero convallis lobortis in in est. Morbi tempus nisi eu diam volutpat tristique.” Pellentesque ligula erat, aliquam ac auctor sit amet, dapibus sed magna: Quisque pharetra ac augue id lacinia. Suspendisse potenti. Morbi ac risus et leo hendrerit fermentum. Vivamus pretium lobortis efficitur. Vestibulum vitae dapibus ipsum. Duis sed arcu eget felis luctus rutrum at ac urna. Sed at risus viverra, faucibus metus nec, rutrum mauris. Morbi vitae ultrices leo. Nunc eu elit laoreet, scelerisque justo quis, consequat orci. Ut feugiat tempor auctor. Mauris lorem dui, malesuada et vulputate placerat, scelerisque vel velit. Mauris non ante quis sapien malesuada finibus. Suspendisse nec tortor lectus. Aenean eget ex at dolor molestie facilisis vitae vel odio. Donec at enim erat. Nam a magna ac orci porttitor sollicitudin. Integer eu sagittis lectus: http://www.businesswire.com. Lorem ipsum Selected Consolidated Financial Data (Dollars in Thousands, Except Per Share Amounts) Unaudited Quarters Ended Six Months Ended June 30, June 30, 2006 2005 % Change 2006 2005 % Change Income statement data: Net interest income $17,985 $16,811 7.0% $35,423 $33,271 6.5% Provision for loan and lease losses 500 500 - 1,000 1,000 - Non-interest income 4,954 4,913 0.8 11,118 9,284 19.8 Common stock data: Net income per share – diluted $0.47 $0.46 2.2% $0.97 $0.90 7.8% Net income per share – basic 0.47 0.46 2.2 0.98 0.90 8.9 Diluted shares outstanding (thousands) 16,808 16,770 16,802 16,752 Contacts Business Wire, San Francisco 415/986-4422
-
TESTtest Testing Lorem Ipsum Dolor Sit Amet
Donec Dictum Iaculis Tellus Suscipit Rhoncus SAN FRANCISCO--(BUSINESS WIRE)--Lorem ipsum dolor sit amet, consectetur adipiscing elit. Nullam fringilla posuere lorem non imperdiet. Morbi blandit, erat eget dapibus blandit, nulla nisl bibendum erat, ut congue sem enim sit amet lorem. Aenean venenatis odio eget augue venenatis feugiat. Nunc suscipit tellus orci. Curabitur iaculis auctor ante eget consectetur. "Sed ipsum nisl, placerat non finibus in, egestas eu ex. Proin ut interdum est, sit amet congue augue." Pellentesque egestas tortor nec dolor dictum posuere. Cras volutpat nunc porttitor, vehicula leo et, mattis sem. Fusce maximus vel velit non viverra. Nam et elit nisi. Curabitur in lacinia turpis. Donec dictum iaculis tellus suscipit rhoncus. Class aptent taciti sociosqu ad litora torquent per conubia nostra, per inceptos himenaeos. Nulla sed consectetur felis. Fusce a nulla in turpis luctus aliquet. Sed posuere velit et diam imperdiet, quis ultricies mauris varius. Vestibulum ante ipsum primis in faucibus orci luctus et ultrices posuere cubilia curae; Fusce vel massa quis ante fringilla scelerisque. Etiam nec metus ut ex facilisis venenatis hendrerit eu enim. Integer et mauris posuere, gravida sapien vitae, pretium purus. Morbi lacinia mattis sapien eu auctor. Duis erat nibh, rutrum non egestas ac, pharetra id nisi. Sed elementum viverra iaculis. Interdum et malesuada fames ac ante ipsum primis in faucibus. Suspendisse potenti. Cras vel leo ligula. Proin fringilla magna augue. Duis id ante nunc. Etiam facilisis orci mi, iaculis lacinia arcu lobortis vitae. Donec ultricies lorem ut ex elementum molestie. Nam sagittis orci eu urna fermentum dictum. Donec tincidunt purus nunc, vel interdum orci aliquam ut. Fusce quis elit at augue tempus tempor. Duis ultricies sodales lorem, sit amet pellentesque turpis laoreet vel. Donec sit amet dapibus mauris. Pellentesque dignissim malesuada accumsan. Integer posuere felis nisi. Mauris at malesuada neque, a mattis lectus. Cras dapibus viverra dolor non egestas. Class aptent taciti sociosqu ad litora torquent per conubia nostra, per inceptos himenaeos. Phasellus quis purus at neque interdum sagittis in ac mi. Vivamus hendrerit efficitur risus quis ultrices. Vivamus vitae nisi viverra, porta erat in, finibus felis. Praesent ultricies odio vitae elit ullamcorper cursus. Nam ut nulla nec est dignissim vulputate. Aenean accumsan felis augue, fringilla eleifend ligula commodo sed. Donec molestie ut ipsum id lacinia. Nullam feugiat augue ac risus pharetra, cursus fermentum purus suscipit. Nam nec scelerisque leo, a posuere lectus. Donec pellentesque ornare risus et eleifend. Vivamus sapien arcu, finibus a tincidunt nec, hendrerit vel erat. Sed a tellus mollis, rutrum dui viverra, rutrum lectus. Maecenas lacinia turpis sit amet sapien vestibulum interdum. Donec volutpat tempus est in condimentum. Etiam vitae rhoncus libero, sed finibus enim. Curabitur consectetur, massa et tristique sollicitudin, lectus quam tincidunt lorem, quis dictum mauris nulla sit amet nunc. Maecenas et turpis tincidunt, tristique purus at, bibendum sapien. Aenean massa leo, lobortis in dapibus non, ullamcorper ut felis. Proin quis accumsan eros. Contacts Test Contact Jane Doe 555/555-1234 0-555-555-555-1234 janedoe@example.comlinkedin.com/jdoeyrjPu2j9
-
Boan Biotech to Present the Pre-clinical Data of Its Proprietary CD3+ T-cell Engager Platform and CEA/CD3 Bispecific Antibody at World Bispecific Summ
Sept. 26, 2021, BOSTON /PRNewswire/ -- Boan Biotech, a subsidiary of Luye Pharma Group, will orally present the pre-clinical data of its proprietary CD3+ T-cell engager platform and CEA/CD3 bispecific antibody at World Bispecific Summit 2021. The annual World Bispecific Summit aiming to promote the development of bispecific antibody therapies will take place for the 12th time this year. It has become a prestigious platform in the industry for academic exchanges. The upcoming event will take place online from September 29 to October 1, 2021 Eastern Standard Time. Details of the oral presentation by Boan Biotech are as follows: Title: Optimization of CD3+ T-cell Engager to Improve Safety ProfileSession: T-cell Based Approaches for Oncology TherapeuticsTime: October 1, 2021 Background CD3+ T-cell engagers are a group of the most promising bispecific antibodies for the treatment of cancers. But they face major challenges including the dose-limiting, life threatening cytokine release syndrome (CRS) toxicity, suboptimal potency, and the on-target off-tumor toxicity. To overcome those challenges, Boan Biotech developed an optimized platform for CD3+ bispecific T-cell engagers with a unique combination of high potency, reduced cytokine release and tumor-targeting selectivity. The CEA/ CD3 bispecific antibody BA1202 is the first clinical candidate developed on the leading bispecific T-cell Engager platform. The pre-clinical research data of BA1202 showed a high potency in killing cancer cells, significantly reduced cytokine release, and superior efficacy. In addition to BA1202, multiple bispecific antibody candidates with similar optimized format and the reduced CD3 affinity have been validated both in vitro and in vivo to have a similar advantage against different solid tumor targets. Boan Biotech plans to speed up the effort to take these bispecific T-cell engagers as investigational drugs to clinical trials, to address the huge unmet needs in treating patients with late-stage cancers. About Boan Biotech As a subsidiary of Luye Pharma Group, Boan Biotech is a fully integrated biopharmaceutical company that specializes in therapeutic antibody development, manufacturing and commercialization with a focus on oncology, immunology, pain, and endocrine diseases. Boan Biotech's antibody discovery work is based on three technology platforms: Human Antibody Transgenic Mouse and Phage Display Technology Platform, Bispecific T-cell Engager Technology Platform and ADC Technology Platform. The company has developed more than 10 innovative antibody product candidates with international intellectual property protection, and 8 biosimilar product candidates, one of which – Boyounuo (Bevacizumab Injection) – has been launched in China. Boan Biotech has expertise in the full industry chain: antibody generation, lead optimization, cell line development, process development, technology transfer, pilot and commercial scale production. The company is also actively exploring other cutting-edge technologies. Its cell therapy products use non-viral vectors for CAR-T for late stage solid tumors. In addition, Boan Biotech is exploring novel off-the-shelf CAR-T and regulatable CAR-T, to develop safer, effective and affordable products for patients. Outside of China, Boan Biotech also pursues biopharmaceutical products development in the US and EU markets.
-
CUPE 4070 Members Ratify New Contract With Swoop
CALGARY, Alberta--(BUSINESS WIRE)--CUPE Flight Attendants working at Swoop, WestJet’s ultra low cost carrier, have signed off on their first collective bargaining agreement. Members voted today to ratify the tentative collective agreement reached in September. The five-year agreement includes wage improvements, and momentum towards industry-standard scheduling and pay rules. “This is the first ever collective agreement for our membership at Swoop. Ratification of this deal is proof positive that certifying with CUPE has been instrumental in our members’ pursuit of fair working conditions,” said CUPE 4070 President Chris Rauenbusch. “Reaching this deal was not easy in light of the circumstances caused by the global pandemic. I’d like to thank both our union and our bargaining committee for working so hard to find a path forward despite the challenges of the past 18 months.” CUPE represents over 200 Flight Attendants at Swoop. The parties have been engaged in collective bargaining towards a first union contract since February 2020. CUPE also represents cabin crew at WestJet mainline and its subsidiary WestJet Encore. :clc/cope 491 Contacts Cheryl Oates, Communications Representative 403-894-3053
-
Emily E. Volk, MD, FCAP, Inaugurated President of the College of American Pathologists
CHICAGO--(BUSINESS WIRE)--#AnnualMeeting--In a ceremony at the College of American Pathologist (CAP) annual meeting in Chicago, Illinois, Emily E. Volk, MD, FCAP, was sworn in as the 37th president of the physician and medical laboratory organization. The CAP, founded in 1946, is the world's largest organization of board-certified pathologists, physicians who specialize in diagnostic pathology and laboratory medicine, and leading provider of laboratory accreditation and proficiency testing programs. “I am dedicated to provide leadership to drive successful execution of our core mission to serve ‘patients, pathologists, and the public by fostering and advocating excellence in the practice of pathology and laboratory medicine worldwide,’” said Dr. Volk, who is also associate professor of pathology at the University of Louisville School of Medicine and the chief medical officer at Baptist Health Floyd in New Albany, Indiana, and “I will work with our members to focus our CAP resources on practicing pathologists to support their daily practice.” Dr. Volk has served on many CAP committees, councils, and task forces. Most notably, she served as president-elect on the CAP Board of Governors, chair of the Ad Hoc Committee for Pathologists Quality Registry, and chair of the Council on Government and Professional Affairs (CGPA). “When my term is over in two years, I’d like to leave the CAP in an even better place, fostering innovation for the profession and CAP services for pathologists to deliver to patients,” stated Dr. Volk. “I’d also like to create more opportunities for pathologists of diverse backgrounds to move into leadership roles. If my role resonates with individuals in healthcare, such as women and minorities, who continue to be underrepresented in leadership roles in their field and gives even one more person the courage to step into a leadership position, my efforts will have been worthwhile.” Dr. Volk received her undergraduate and medical degree from the University of Missouri-Kansas City and her Master of Business Administration from the University of Massachusetts. She completed her residency in Anatomic and Clinical Pathology at the Cleveland Clinic Foundation and completed a fellowship in Cytopathology at the William Beaumont Hospital in Royal Oak, Michigan. Prior to her current position in New Albany, she was senior vice president of clinical services at the University Health System, San Antonio, Texas, and clinical assistant professor of pathology at the University of Texas Health Long School of Medicine. About the College of American Pathologists As the world's largest organization of board-certified pathologists and leading provider of laboratory accreditation and proficiency testing programs, the College of American Pathologists (CAP) serves patients, pathologists, and the public by fostering and advocating excellence in the practice of pathology and laboratory medicine worldwide. For more information, read the CAP Annual Report. Contacts Catherine Dolf, Sr. Manager, Media Relations CAP, 847-832-7472, cdolf@cap.orgAbby Watson, Manager, Communications CAP, 847-832-7513, awatson@cap.org
-
Donald S. Karcher Becomes President-Elect of College of American Pathologists
CHICAGO--(BUSINESS WIRE)--#AnnualMeeting--In a ceremony at the College of American Pathologists (CAP) annual meeting in Chicago, Illinois, Donald S. Karcher, MD, FCAP, was sworn in as president-elect of the physician and medical laboratory organization. The CAP, founded in 1946, is the world's largest organization of board-certified pathologists, physicians who specialize in diagnostic pathology and laboratory medicine, and leading provider of laboratory accreditation and proficiency testing programs. “As president-elect, I hope to further reinforce the CAP as a strong advocate for our profession, maximally useful resource for our members and customers, and effective partner as we provide the best possible care for our patients,” said Dr. Karcher, who is a professor of pathology and practicing hematopathologist at George Washington University, Washington, DC. “Our members and our patients should be at the center of everything we do in the CAP.” Dr. Karcher has been an active CAP member for years, serving on the Board of Governors and as chair of the Council on Government and Professional Affairs, the Council on Education, the Pathologist Pipeline Ad Hoc Committee, and the Value-Based Care Strategy Steering Group. He has advocated for fair pay for pathologists and worked to help provide great educational resources for pathologists and other clinical laboratorians. “I look forward to helping prepare pathologists for emerging technologies in pathology practice, such as digital pathology and artificial intelligence,” stated Dr. Karcher. “I’m also excited about helping pathologists become increasingly visible to patients, including providing direct consultation to patients and their families.” Dr. Karcher received his medical degree from Louisiana State University School of Medicine New Orleans. He completed his internship and residency at Brooke Army Medical Center at Fort Sam Houston in San Antonio. After 20 years of serving as the chair of pathology at George Washington University, he recently stepped down as chair to resume his current roles there. About the College of American Pathologists As the world's largest organization of board-certified pathologists and leading provider of laboratory accreditation and proficiency testing programs, the College of American Pathologists (CAP) serves patients, pathologists, and the public by fostering and advocating excellence in the practice of and laboratory medicine worldwide. For more information, read the CAP Annual Report. Contacts Catherine Dolf, Sr. Manager, Media Relations CAP, 847-832-7472, cdolf@cap.orgAbby Watson, Manager, Communications CAP, 847-832-7513, awatson@cap.org
-
UWM Launches “BOLT”, Giving Mortgage Brokers Tools to Achieve 15 Minute Initial Approval
Lender’s proprietary technology clears path for faster loan approvals, fewer touches and more certainty for brokers PONTIAC, Mich.--(BUSINESS WIRE)--United Wholesale Mortgage, (UWM), the #1 wholesale and purchase lender in America, announced today the launch of BOLT, a self-service platform that provides the ability to get an initial approval for qualified borrowers in just 15 minutes. Mat Ishbia, president and CEO of UWM made this announcement today at the Association of Independent Mortgage Experts (AIME) live Fuse event. This revolutionary tool utilizes data extraction, auto doc recognition and smart technology to input information from items such as driver’s licenses, income statements, county records and more. It will also create efficiency by providing brokers access to the same income calculator used by UWM underwriters, and, using automated tools and artificial intelligence, will notify the user of any potential discrepancies. “We’ve demonstrated time and time again with our proprietary technology, including UClose, our InTouch Mobile app, and one-click AUS, that we’re leading the way to making the loan process faster and easier without compromising quality in any way,” said Ishbia. “With BOLT, brokers will now have the control, speed and certainty they need to get loans to the closing table faster than ever before.” The new feature can be found in UWM’s loan origination system, EASE. When brokers upload a loan application with required documentation, they will then be able to elect to use BOLT. This will provide them with a step-by-step process that will allow them to complete the initial approval when it’s convenient for them, creating a faster experience and fewer underwriting touches. “We're going to remember BOLT as a significant development in the mortgage industry that forever changed the way underwriting is done,” said Ishbia. “UWM built this technology, which uses things like doc recognition and indexing. This will allow initial approval of the file to be completed in minutes rather than hours, while also ensuring guardrails and quality standards are in place, as they always are with UWM, to close clean loans." At the AIME Fuse event, UWM also announced the launch of The Source, a new customizable search engine that delivers the information brokers need, all in one place. This includes all guidelines, all interpretations, industry news and UWM product updates. Instead of sending users to other locations to find information, The Source searches multiple databases and uses smart search technology to generate fast, relevant results based on past and popular searches. It is also completely customizable, allowing users to bookmark the information they need and reference the most. UWM supports independent mortgage brokers with industry-leading training, technology and service. For more information on how to sign up as a broker with UWM, visit www.UWM.com. About UWM Holdings Corporation and United Wholesale Mortgage Headquartered in Pontiac, Michigan, UWM Holdings Corporation (UWM) is the publicly traded indirect parent of United Wholesale Mortgage. UWM is the #1 wholesale lender in the nation six years in a row, providing state-of-the-art technology and unrivaled client service. UWM is known for its highly efficient, accurate and expeditious lending support. UWM underwrites and provides closing documentation for residential mortgage loans originated by independent mortgage brokers, correspondents, small banks and local credit unions. UWM's exceptional teamwork and laser-like focus on delivering innovative mortgage solutions are driving the company's ongoing growth and its leadership position as the foremost advocate for mortgage brokers. For more information, visit www.uwm.com or call 800-981-8898. NMLS #3038. Contacts NICOLE ROBERTS, PR Strategist (248) 833-4287 Nroberts1@uwm.com
-
The Law Offices of Frank R. Cruz Continues Investigation of InnovAge Holding Corp. (INNV) on Behalf of Investors
LOS ANGELES--(BUSINESS WIRE)--$INNV #investors--The Law Offices of Frank R. Cruz continues its investigation of InnovAge Holding Corp. (“InnovAge” or the “Company”) (NASDAQ: INNV) on behalf of investors concerning the Company’s possible violations of federal securities laws. If you are a shareholder who suffered a loss, click here to participate. On September 21, 2021, after the market closed, InnovAge revealed that the Centers for Medicare and Medicaid Services (“CMS”) had “determined to freeze new enrollments at [the Company’s] Sacramento center based on deficiencies detected in [a recent] audit.” The Company stated that these “deficiencies relate to failures to provide covered services, provide accessible and adequate services, manage participants’ medical situations, and oversee use of specialists, among others.” On this news, the Company’s stock price fell $2.90, or nearly 25%, to close at $8.75 per share on September 22, 2021, thereby injuring investors. Follow us for updates on Twitter: twitter.com/FRC_LAW. If you purchased InnovAge securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Frank R. Cruz, of The Law Offices of Frank R. Cruz, 1999 Avenue of the Stars, Suite 1100, Los Angeles, California 90067 at 310-914-5007, by email to info@frankcruzlaw.com, or visit our website at www.frankcruzlaw.com. If you inquire by email please include your mailing address, telephone number, and number of shares purchased. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules. Contacts The Law Offices of Frank R. Cruz, Los Angeles Frank R. Cruz, 310-914-5007 fcruz@frankcruzlaw.comwww.frankcruzlaw.com
